Roberto Stancampiano

Cagliari, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Corrigendum to "Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease" [Experimental neurology 2023 May;363:114370].

Corrigendum to "Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease" [Experimental neurology 2023 May;363:114370].

Journal: Experimental neurology
Published: December 16, 2023

Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.

Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.

Journal: Experimental neurology
Published: September 30, 2022

Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update.

Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update.

Journal: Progress in brain research
Published: March 31, 2021

BDNF Overexpression Increases Striatal D3 Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia.

BDNF Overexpression Increases Striatal D3 Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia.

Journal: Journal of Parkinson's disease
Published: July 12, 2020

Essential fatty acids deficient diet modulates N-Acylethanolamide profile in rat's tissues.

Essential fatty acids deficient diet modulates N-Acylethanolamide profile in rat's tissues.

Journal: Prostaglandins, leukotrienes, and essential fatty acids
Published: June 27, 2019

5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction.

5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction.

Journal: Neurobiology of disease
Published: June 01, 2018

The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.

The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.

Journal: Experimental neurology
Published: December 12, 2016

Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.

Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.

Journal: Neurobiology of disease
Published: August 06, 2015

Effect of selective and non-selective serotonin receptor activation on L-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats.

Effect of selective and non-selective serotonin receptor activation on L-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats.

Journal: Behavioural brain research
Published: April 09, 2015

Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

Journal: Neuroscience
Published: January 30, 2015

Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.

Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.

Journal: Neuroscience
Published: December 19, 2013

The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.

The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.

Journal: Neurobiology of disease
Published: July 26, 2013
Showing 1-12 of 14

Last Updated: 09/26/2026